Repare Therapeutics Inc.
RPTX
$1.59
$0.042.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -76.70% | -- | -100.00% | -- | -96.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.70% | -- | -100.00% | -- | -96.45% |
| Cost of Revenue | -52.51% | -38.52% | 8.25% | -13.17% | -10.99% |
| Gross Profit | 51.61% | -204.30% | -20.45% | 7.03% | -719.50% |
| SG&A Expenses | -27.51% | -11.21% | -19.92% | -18.10% | -4.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.09% | -32.86% | -29.87% | -14.13% | -9.68% |
| Operating Income | 46.24% | -358.15% | 0.23% | 9.30% | -204.45% |
| Income Before Tax | 52.11% | -315.16% | -2.98% | 3.57% | -289.86% |
| Income Tax Expenses | -23.93% | -41.18% | -100.00% | 102.98% | -89.52% |
| Earnings from Continuing Operations | 51.85% | -328.26% | -2.29% | -82.24% | -191.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.85% | -328.26% | -2.29% | -82.24% | -191.09% |
| EBIT | 46.24% | -358.15% | 0.23% | 9.30% | -204.45% |
| EBITDA | 48.34% | -336.25% | 0.06% | 9.37% | -213.40% |
| EPS Basic | 52.39% | -326.38% | -1.38% | -80.75% | -188.69% |
| Normalized Basic EPS | 46.10% | -289.86% | -2.62% | 8.67% | -286.59% |
| EPS Diluted | 52.39% | -336.67% | -1.38% | -80.75% | -188.69% |
| Normalized Diluted EPS | 46.10% | -297.91% | -2.62% | 8.67% | -286.59% |
| Average Basic Shares Outstanding | 1.12% | 0.85% | 0.88% | 0.83% | 0.85% |
| Average Diluted Shares Outstanding | 1.12% | -3.25% | 0.88% | 0.83% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |